Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  New England Journal of Medicine

• Publication date

  2004-10-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA040720PMID 15470213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Cancer Facts & Figures 2004

  2004cited by this paper
• The antiandrogen withdrawal syndrome

  2004cited by this paper
• Current strategies in the management of hormone refractory prostate cancer.

  2003cited by this paper
• Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer

  2003cited by this paper
• Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.

  2003cited by this paper
• A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

  2003cited by this paper
• Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

  2003cited by this paper
• Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.

  2002cited by this paper
• Chemotherapy for androgen-independent prostate cancer.

  2002cited by this paper
• A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

  2002cited by this paper
• The potential role of bisphosphonates in prostate cancer

  2002cited by this paper
• Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.

  2001cited by this paper
• Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.

  2001cited by this paper
• The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.

  2001cited by this paper
• Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.

  2001cited by this paper
• Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

  2001cited by this paper
• A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.

  2000cited by this paper
• Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.

  2000cited by this paper
• Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.

  2000cited by this paper
• Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.

  1999cited by this paper
• Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.

  1999cited by this paper
• A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.

  1999cited by this paper
• Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

  1999cited by this paper
• Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

  1997cited by this paper
• Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance.

  1997cited by this paper
• Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

  1996cited by this paper
• Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

  1989cited by this paper
• The McGill Pain Questionnaire: Major properties and scoring methods

  1975cited by this paper

• Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany.

  2026cites this paper
• Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial.

  2026cites this paper
• Suppression of PARP1 enhances PTEN mRNA therapy in castration-resistant prostate cancer by glycolysis disruption

  2026cites this paper
• Comparison of weekly docetaxel regimens in prostate cancer: a systematic review and frequentist network meta-analysis.

  2026cites this paper
• Séquences abiratérone–chimiothérapie–enzalutamide versus enzalutamide–chimiothérapie–abiratérone dans le CPRCm : étude retrospective

  2026cites this paper
• Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

  2026cites this paper
• Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.

  2026cites this paper
• Drug re-purposing to improve outcomes in the management of prostate cancer – aims, outcome measures and design of current phase III trials

  2026cites this paper
• Boolean network-based identification of optimal drug combinations for prostate cancer

  2026cites this paper
• Chemotherapy-Forward Management of Advanced Prostate Cancer: Taxane Timing, Sequencing and the Real-World Place of Immunotherapy.

  2026cites this paper
• Long-Term Oncological Outcomes in Metastatic Prostate Cancer Patients Who Are Able to Maintain/Recover Ongoing Anticancer Therapy After SARS-CoV-2 Infection—Results of the MEET-URO 22 Study

  2026influential citation
• A REtrospective Study to Describe the Real-World Treatment Landscape in Patients with Metastatic Castration-Resistant PROstate Cancer: REMPRO.

  2026cites this paper
• Integrating virtual screening and molecular dynamics simulations to identify emodin as a PYCR1 inhibitor modulating docetaxel sensitivity in prostate cancer

  2026cites this paper
• Enhancing docetaxel efficacy in prostate cancer: the synergistic role of thymus vulgaris extract in inducing apoptosis and autophagy.

  2026cites this paper
• The proteostasis paradox: from systemic collapse in aging to pathway-specific addiction in prostate cancer

  2026cites this paper
• Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

  2026cites this paper
• Bibliometric analysis of bone metastasis from prostate cancer research from 2007 to 2024.

  2026cites this paper
• Impact of Curcuma longa on Hematopoiesis and Splenic Mass in an Animal Model Undergoing Docetaxel Chemotherapy

  2026cites this paper
• PEGylated Zein Micelles for Prostate Cancer Therapy: Influence of PEG Chain Length and Transferrin Targeting on Docetaxel Delivery

  2026cites this paper
• Real-Life Use Patterns of Androgen Receptor Pathway Inhibitors (ARPIs): A Nationwide Register-Based Study in Finland During 2012–2023

  2025cites this paper
• Docetaxel Rechallenge After Chemohormonal Therapy in High-Volume Metastatic Castration-Sensitive Prostate Cancer

  2025cites this paper
• Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

  2025cites this paper
• Androgen receptor as a potential therapeutic target in castration-resistant prostate cancer: a bibliometric analysis (2005–2024)

  2025cites this paper
• Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T‐Cell Engager, in Prostate Cancer Patients

  2025cites this paper
• Immunotherapy in metastatic prostate cancer

  2025cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-resistant prostate cancer (Update).

  2025cites this paper
• Resilience and vulnerabilities of tumor cells under purine shortage stress.

  2025cites this paper
• Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions

  2025cites this paper
• Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer.

  2025cites this paper
• Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

  2025cites this paper
• The contemporary management of prostate cancer

  2025cites this paper
• Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia

  2025cites this paper
• Lycopene as a potential anticancer agent: Current evidence on synergism, drug delivery systems and epidemiology (Review)

  2025influential citation
• Targeting SREBP-dependent lipogenesis potentiates the anti-tumor activity of docetaxel by increasing membrane permeability and intracellular drug accumulation

  2025cites this paper
• Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)

  2025cites this paper
• AI-driven software for automated quantification of skeletal metastases and treatment response evaluation using whole-body diffusion-weighted MRI (WB-DWI) in advanced prostate cancer

  2025cites this paper
• Reading and Interpreting Quality-of-Life Results in Cancer Trials.

  2025cites this paper
• Urolithins: Emerging natural compound targeting castration-resistant prostate cancer (CRPC).

  2025cites this paper
• Socioeconomic inequities in prostate cancer care: private versus public treatment settings pose a significant impact on overall survival

  2025cites this paper
• Effects of empagliflozin and its combination with docetaxel on LNCaP and DU- 145 prostate cancer cell lines: cytotoxicity and molecular pathway analysis

  2025influential citation
• Exploring the impact of cuproptosis on prostate cancer prognosis via RNA methylation regulation based on single cell and bulk RNA sequencing data

  2025cites this paper
• Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy

  2025cites this paper
• Twenty-one-year report from the Danish Health Authority Expert Advisory Panel for review of treatment of 10 000 cancer patients

  2025cites this paper
• Toxicities of taxane-based chemotherapy in prostate cancer

  2025cites this paper
• Leveraging Nanotechnology: Innovative Strategies, Challenges, and Future Directions in Targeted Prostate Cancer Therapy

  2025cites this paper
• A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer.

  2025cites this paper
• STEAP1: a promising target in prostate cancer therapy.

  2025cites this paper
• Osteosclerotic changes on computed tomography predict disease progression and poor survival in prostate cancer with osteoblastic metastases

  2025cites this paper
• Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancer

  2025cites this paper
• Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapy.

  2025cites this paper
• Comparative Effectiveness of First‐Line Treatments for Castration‐Resistant Prostate Cancer: A Large‐Scale Retrospective Study in Japan

  2025cites this paper
• Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

  2025cites this paper
• Survival improvements and disparities in metastatic prostate adenocarcinoma, clear cell renal cell carcinoma, and urothelial carcinoma of bladder

  2025cites this paper
• Drug-like molecules targeting androgen receptor's allosteric binding sites selected by augmented AI and high-throughput screening as antitumor agents against prostate cancer.

  2025cites this paper
• Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches

  2025cites this paper
• Management of Metastatic Prostate Cancer

  2025cites this paper
• Pilot experience of [161Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry

  2025cites this paper
• The role of LKB1 in prostate cancer: implications for tumor progression and therapy

  2025cites this paper
• Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer.

  2025cites this paper
• Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site‐Directed Therapy for Castration‐Resistant Prostate Cancer

  2025cites this paper
• A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors

  2025cites this paper
• 177Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.

  2025cites this paper
• Real‑world data on the outcomes of upfront docetaxel in hormone‑sensitive metastatic prostate cancer.

  2025cites this paper
• Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer.

  2025cites this paper
• Drug treatment options of high-risk biochemically recurrent prostate cancer based on efficacy and safety: a systematic review and Bayesian network analysis

  2025cites this paper
• Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer

  2025cites this paper
• Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience

  2025cites this paper
• Resilience and vulnerabilities of tumor cells under purine shortage stress

  2025cites this paper
• Impact of Body Mass Index on Survival After Docetaxel Chemotherapy for Metastatic Castration‐resistant Prostate Cancer

  2025cites this paper
• Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC

  2025influential citation
• Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy

  2025cites this paper
• Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy

  2025cites this paper
• Comparative therapeutic efficacy and safety of first-line and second-line therapies for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

  2025cites this paper
• Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial

  2025cites this paper
• Pleural Metastasis as an Initial Presentation of Prostate Cancer: Case Report and Literature Review

  2025cites this paper
• Carboxymethyl Dextran-Based Drug Delivery Systems: Advances, Challenges, and Applications in Cancer Therapy

  2025cites this paper
• Fatty acid metabolism related gene MECR contributes to the progression of prostate cancer

  2025cites this paper
• The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo

  2025cites this paper
• Men’s experiences of decision-making in life-prolonging treatments of metastatic castration-resistant prostate cancer – wishing for a process adapted to personal preferences: a prospective interview study

  2025cites this paper
• Targeting the tumour cell surface in advanced prostate cancer

  2025cites this paper
• Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer

  2025cites this paper
• Chemotherapy and Heart-Specific Mortality in Elderly Men with Prostate Cancer: A Propensity Score Matching Analysis

  2025cites this paper
• Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review

  2025cites this paper
• Temporal effect of docetaxel on bone quality in a rodent model of vertebral metastases

  2025cites this paper
• Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment Sequences

  2025cites this paper
• Interplay Between the Cytoskeleton and DNA Damage Response in Cancer Progression

  2025cites this paper
• Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.

  2025cites this paper
• 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).

  2025cites this paper
• A Case Report of a Patient with Multiple Bone Metastases from Prostate Cancer Achieving Complete Remission for 6 Years after Chemotherapy Combined with Endocrine Therapy

  2025cites this paper
• PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient Cohort.

  2025cites this paper
• Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.

  2025cites this paper
• Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.

  2025cites this paper
• Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada

  2025cites this paper
• Local Therapy Can Enhance the Prognosis of Certain Patients with Pathologically Diagnosed Neuroendocrine Prostate Carcinoma

  2025cites this paper
• Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study

  2025cites this paper
• A Review of Sipuleucel-T in Combination with Other Therapies for Metastatic Castration-Resistant Prostate Cancer

  2025cites this paper
• Recent advances in drug treatment for prostate cancer

  2025influential citation
• Packing the Punch: Current and Emerging Treatment Strategies in Metastatic Castration-Sensitive Prostate Cancer

  2025cites this paper
• Exploring the Therapeutic Potential of 177Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases

  2025cites this paper
• The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: a narrative review.

  2025cites this paper